Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
RESEARCH TOOLSreports
Holding SNDX?
Track your performance easily
SNDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.14 - $25.34
Previous Close$21.78
Volume8.37M
Average Volume (3M)948.06K
Market Cap
$1.86B
Enterprise Value$1.47B
Total Cash (Recent Filing)$389.61M
Total Debt (Recent Filing)$842.00K
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 05, 2025EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.63
Shares Outstanding85,357,675
10 Day Avg. Volume2,005,438
30 Day Avg. Volume948,062
Standard Deviation0.16
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.78
Price to Sales (P/S)116.19
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue91.90
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.02
Forecast
1Y Price Target
$35.10Price Target Upside116.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Syndax Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company expects it has a cash runway, when including the $350M from the recently announced Niktimvo royalty agreement, to fund operations through profitability.
Market OpportunitySyndax estimates there is an approximately $750M to $1.25B U.S. market opportunity in r/r mNPM1 acute leukemia.
Regulatory MilestonesSyndax is eligible to receive up to $220M in future development and regulatory milestones and up to $230M in commercialization milestones.
Bears Say
Product CompetitivenessIncreased uncertainty concerning revumenib's competitiveness, prompting a cautious outlook ahead of its pivotal readout.
Regulatory DelaysSentiment taking a hit following FDA’s recent 3 months PDUFA extension to menin inhibitor revumenib.
Sales ForecastsSales forecasts for axatilimab are being lowered due to its IV form being seen as a major drawback by prescribers.
---
Ownership Overview
5.98% Insiders
19.11% Mutual Funds
4.38% Other Institutional Investors
56.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $13.14 and its highest was $25.34 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is Mar 05, 2025 which is in 104 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Nov 05, 2024. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.07 by $0.09.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -$0.32.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 85,357,670 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.07. Following the earnings report the stock price went up 8.431%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Among the largest hedge funds holding Syndax Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Syndax Pharmaceuticals Inc’s shares valued at 32M.
---
Syndax Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.10 (116.53% Upside)
$35.10 (116.53% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 983.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
60.73%
12-Months-Change
Fundamentals
Return on Equity
-81.88%
Trailing 12-Months
Asset Growth
6.66%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
---
SNDX Company Deck
---
SNDX Earnings Call
Q3 2024
0:00 / 0:00
---
SNDX Stock 12 Month Forecast
Average Price Target
$35.10
▲(116.53% Upside)
Technical Analysis
Best Analysts Covering SNDX
1 Year
1 Year Success Rate
14/17 ratings generated profit
1 Year Average Return
+40.48%
reiterated a buy rating 15 days ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +40.48% per trade.
---